Skip to main content
. Author manuscript; available in PMC: 2015 Feb 14.
Published in final edited form as: Proteomics. 2010 Nov;10(21):3800–3810. doi: 10.1002/pmic.201000297

Figure 5. Prediction of clinical outcome based on a 23-gene signature.

Figure 5

Kaplan-Meier analysis was performed to predict the probability of metastasis-free survival using published microarray datasets. a) Microarray dataset from Wang group [30]. This data set includes 286 lymph node-negative breast cancer patients who received no adjuvant treatment when clinical samples were collected. b) Microarray dataset from van de Vijver group [31]. A total of 295 patients had stage I or II breast cancer and were younger than 53 years old; 151 had lymph-node-negative disease, and 144 had lymphnode- positive disease. X axis represents time of survival. Y axis represents the probability of metastasis-free survival. MFS, metastasis-free survival